- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Cytogen launches brachytherapy product
Radiopharmaceutical developer Cytogen has commercially released a new brachytherapy implant for the treatment of localized prostate cancer. DraxImage, the radiopharmaceutical subsidiary of Draxis Health, developed the next-generation radioactive seed,
Radiopharmaceutical developer Cytogen has commercially released a new brachytherapy implant for the treatment of localized prostate cancer. DraxImage, the radiopharmaceutical subsidiary of Draxis Health, developed the next-generation radioactive seed, called BrachySeed Palladium-103. This is the second such offering by Cytogen and DraxImage. The first, BrachySeed I-125 containing radioactive iodine, was launched in 2001. The BrachySeed products complement Cytogen's ProstaScint, a monoclonal antibody-based agent used to image the extent and spread of prostate cancer.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.
Could a Newly FDA-Cleared C-Arm Device Bolster Efficiency for Interventional Radiologists?
April 22nd 2024In addition to advanced imaging quality and dose efficiency, the Philips Zenition 30 mobile C-arm device emphasizes personalized user profiles and automated customization to help reduce procedure time.
